# Quality Gates Assessment — WHY1 Phase

**Run ID**: squad-1775164062  
**Phase**: WHY1 (SAGE validation)  
**Date**: 2026-04-02  
**Scoring Method**: 0-10 scale per artifact, 4 dimensions: Coverage, Consistency, Evidence, Actionability  

---

## Artifact Quality Scores

| Artifact | Coverage | Consistency | Evidence | Actionability | Overall | Grade |
|----------|----------|-------------|----------|---------------|---------|-------|
| glossary.md | 9 | 9 | 8 | 9 | **8.75** | A |
| mental-model.md | 9 | 8 | 7 | 8 | **8.0** | A |
| novelty-catalogue.md | 8 | 7 | 6 | 7 | **7.0** | B+ |
| inter-process-effectiveness.md | 7 | 8 | 5 | 8 | **7.0** | B+ |
| assumptions.md | 9 | 8 | 4 | 7 | **7.0** | B+ |
| boundaries.md | 8 | 8 | 6 | 7 | **7.25** | B+ |
| unknowns.md | 9 | 8 | 7 | 8 | **8.0** | A |
| synthesis-report.md | 8 | 8 | 7 | 8 | **7.75** | A- |
| reasoning-journal.json | 7 | 9 | 8 | 6 | **7.5** | B+ |
| proof-status-table.md | 9 | 9 | 8 | 9 | **8.75** | A |

---

## Dimension Scores — Detailed Assessment

### Coverage: Does it cover all necessary ground?

**Excellent (9)**: Comprehensive scope, no major gaps
- **glossary.md (9)**: All 42 agents named, all 7 tiers covered, all key mechanisms defined (endocrine, belief system, contradiction scanner, RADAR, constitutional gate, calibration, token-gating, 7-tier specialization, NS-003). Acronyms and belief terms also covered.
- **assumptions.md (9)**: 15 assumptions documented across critical (A-001 to A-006), standard (A-007 to A-010), low-risk (A-011 to A-013), and spec-015-specific (A-014 to A-015). Dependency graph included.
- **unknowns.md (9)**: 10 known unknowns, 5 potential unknown-unknowns, summary table. All major areas of uncertainty captured.
- **proof-status-table.md (9)**: All 17 rows present (per AC-001-001 verification). Rows 1-5 (core novelties), rows 6-10 (CA overlays), rows 11-12 (AC-3 and use cases), rows 13-17 (token reduction, additional use cases).

**Good (8)**: Major areas covered, minor gaps acceptable
- **boundaries.md (8)**: Internal boundaries (7 tiers), external boundaries (codebase, user, LLM, knowledge base, spec directory, config, constitution, RADAR, git), trust boundaries (5 categories), data ownership (10+ artifacts), tiering rules. Gap: doesn't detail all inter-tier communication protocols (data passing between EXPLORATION→FEASIBILITY→SOLUTION, for example).
- **novelty-catalogue.md (8)**: 8 novel mechanisms (NOVEL-001 through NOVEL-008) listed with evidence and patent defensibility ranking. Gap: doesn't cover all combinatorial novelty (e.g., is endocrine + belief system combination novel beyond the two separately?).
- **mental-model.md (9)**: Core entities (Agent, Phase, Tier, State, Quality Gate, Hormone, Constitution), relationships (7 cardinalities), concept map (data flow), behavioral patterns (6 patterns), execution models (BANZAI, standard), authority/escalation (3 tiers), critical dependency chains (4 chains), unknowns/complexity (5 areas). Comprehensive entity-relationship coverage.
- **synthesis-report.md (8)**: Cross-document contradictions, synthesis (core system definition, novelties, risks, patent claims, inter-process effectiveness, evidence gaps). Covers contradiction analysis, novelty ranking, patent strategy, and effectiveness assessment. Gap: doesn't detail all individual agent functions (focuses on system-level rather than agent-level detail).

**Fair (7)**: Covers main areas, some gaps
- **inter-process-effectiveness.md (7)**: Data flows between 6 tier transitions (DISCOVER→WHY, WHY→WHAT, WHAT→ASSESS, ASSESS→HOW, HOW→PLAN, PLAN→BUILD, BUILD→LEARN), state.json tracking, 4 quality gates (SAGE, GATEKEEPER, BUILD multi-gate, effectiveness summary), bottlenecks (5 identified), token efficiency (BANZAI allocation), knowledge base feedback loop, critical path summary. Gap: doesn't detail all intra-phase communication (e.g., SCOUT→SYNTHESIZER within DISCOVER phase is mentioned but not deeply analyzed).

### Consistency: Are claims internally consistent?

**Excellent (9)**: No contradictions, all claims reinforce
- **glossary.md (9)**: All agent names, tiers, and functions consistent with mental-model.md. Hormone definitions match endocrine.sh. No circular definitions or contradictions.
- **proof-status-table.md (9)**: All 17 rows internally consistent. Rows 1-2 (PROVEN/PARTIAL), rows 3-5 (NOVELTY/NOT PROVEN/SPECULATION), rows 6-10 (all GATE-CONDITIONED), rows 11-17 (varied status). No inconsistency in status assignments.
- **reasoning-journal.json (9)**: Entries chronologically ordered, reasoning chains internally coherent. No contradictory evidence in successive entries.

**Good (8)**: Minor inconsistencies resolved
- **mental-model.md (8)**: Defines "HOW" as both agent codename and phase name (overloaded term table, line 135-144). Resolved by explicit overloaded terms table showing all 3 contexts. Data ownership (Table line 176) states CONTROL "owns agents that run in all phases" but SCOREKEEPER actually runs only in specified phases. Minor; context clarifies.
- **assumptions.md (8)**: A-001 through A-015 consistent with unknowns.md (U-001 through U-010). Dependency graph (lines 126–145) shows how assumptions block each other. Circular dependency possible (A-003 depends on A-001 depends on A-003?) but breaks at explicit dependencies: A-003 DISCOVER must precede WHAT, A-001 Opus capability is independent assumption. Consistent overall.
- **boundaries.md (8)**: "No cross-tier leakage" rule stated; later admits escalation for violations (lines 169–170). Not contradictory (escalation is enforcement) but could be clearer that violations are caught, not prevented.

**Fair (7)**: Some conflicts require interpretation
- **novelty-catalogue.md (7)**: NOVEL-006 (Constitutional Gate) claims "novel for LLM orchestration" but agents/control/commander.md already describes the gate. Resolution: novelty is the combination of immutable principles + pre-dispatch enforcement; gate concept is not novel, but application is. Requires careful reading; not explicitly contradictory but potentially confusing.
- **inter-process-effectiveness.md (7)**: Claims SAGE gate "catches ~30% of first-pass specs" (line 91) but later describes improvement "from ~70% to ~90% after amendments" (line 101). Not contradictory (30% catch rate, 70% pass rate; 90% after 1-2 re-runs). Labeling inconsistency (percent pass vs percent fail) makes reading harder.

### Evidence Quality: Are claims backed by evidence?

**Excellent (8)**: Papers cited, measurements provided
- **proof-status-table.md (8)**: All 17 rows cite sources: arxiv papers (NL2GenSym, Kumiho, Speculative Decoding, CoALA, ADaPT), standards (IEEE 830, CSP literature), and systematic search (U-015-002 referenced). Evidence grades assigned (A/B/C/D). Strong grounding.
- **glossary.md (8)**: Endocrine system cites "scripts/bash/endocrine.sh (1047 lines)" and "squad-config.yml hormone baselines" (lines 111). Belief system cites "scripts/belief-parser.py (547 lines)" (line 112). RADAR cites "radar/server.py, radar/emitter.py" (line 114). Evidence trails to code.

**Good (7)**: Some measurement, some estimation
- **unknowns.md (7)**: U-001 to U-010 all have "Who can answer" and "Validation approach" sections. Evidence is documented requirements (what would prove/disprove), not actual measurements. U-007 through U-010 marked as "must-resolve"; no current evidence but clear acceptance criteria documented (e.g., "AQS(CA) > AQS(baseline) + 10 pp, p < 0.05" for U-CA-004).
- **synthesis-report.md (7)**: Section 3 cites papers for patent claims (e.g., "NL2GenSym's 86%+ schema compliance on Soar rule generation" per arxiv:2510.09355). Section 4 references pattern confidence data (PAT-001 through PAT-006, 0.79-0.88 confidence) from "squad-run-001" but pattern data not shown in this artifact (assumed in knowledge-base/patterns.yaml). Evidence graded but not all evidence shown in this report.

**Fair (6)**: Mostly design estimates, some references
- **novelty-catalogue.md (6)**: Novelties described (e.g., "endocrine.sh (1047 lines)", "scripts/belief-parser.py (547 lines)", "scripts/contradiction-scanner.py (778 lines)" — line counts provided but code not analyzed in this artifact). Patent defensibility ranked but with limited evidence (no systematic search shown in this document for NOVEL-001 through NOVEL-008, though synthesis-report references U-015-002 for NS-003).
- **assumptions.md (4-6)**: A-001 through A-015 state "Status: UNVALIDATED" or "Partially validated." Validation methods documented but not executed. No empirical measurement provided. Evidence exists (documented in config files, code), but not directly shown or measured.
- **inter-process-effectiveness.md (5)**: Estimates labeled as "(est.)" throughout. SAGE gate "~70% (first pass)" (line 91), "~90% pass after 1–2 re-runs" (line 101). Pattern confidence (lines 249–256) is from squad-run-001 but pattern data not detailed. Token efficiency claims (lines 168–175) are "hypothesized" not measured.
- **boundaries.md (6)**: External boundaries listed (codebase, user, LLM, knowledge base, etc.) with "Dependency strength" labeled (hard/soft) but no measurement of actual dependency failures, latency, or data flow rates. Design-level classification, not empirical.

**Poor (4-5)**: Mostly speculative
- **mental-model.md (7)**: Behavioral patterns documented (dispatch sequencing, amendment loop, gate-conditioned claims, EVOI routing, hormone feedback, belief annotation, contradiction detection). Patterns described but not validated with measurements. Example: "adrenaline [0.7], dopamine [0.5] (execution mode)" — specific values assigned but no evidence they produce desired effect.

### Actionability: Can downstream agents use this?

**Excellent (9)**: Clear decisions, testable criteria, ready for next phase
- **glossary.md (9)**: All 42 agents named and assigned to tier; all key terms defined with explicit context (not overloaded when possible). CARTOGRAPHER can read this and know exactly which agents exist and their responsibilities. Ready for WHAT phase.
- **proof-status-table.md (9)**: Every row specifies "What Would Constitute Full Proof" (column 8). ARCHITECT can read row 6 (Goal Stack) and know: U-CA-004 must resolve POSITIVE, plus measurable reduction in routing failure rate. Clear decision criteria.
- **unknowns.md (9)**: Every unknown has "Who can answer," "Priority," "Validation approach." COMMANDER can read U-007 and dispatch INVESTIGATOR with exact success criterion: "AQS(CA) > AQS(baseline) + 10 pp, p < 0.05." Actionable.

**Good (8)**: Mostly actionable, some gaps
- **mental-model.md (8)**: Concept map (lines 189–222) shows data flow DISCOVER → WHAT → ASSESS → HOW → PLAN → BUILD → LEARN. CARTOGRAPHER can use this to understand inputs/outputs of each phase. Behavioral patterns (lines 226–320) describe "Pattern: Dispatch Sequencing" with example (DISCOVER phase, steps 1-4). Actionable for understanding expected execution. Gap: amendment loop (lines 241–255) documents the pattern but doesn't give CARTOGRAPHER a decision rule ("how do I know when to stop amending?").
- **synthesis-report.md (8)**: Section 3 (Patent defensibility) ranks claims Priority 1-4. Section 5 (Evidence gaps) lists "Evidence Needed to Upgrade." LEGAL team can read Priority 1 (NS-003, Endocrine, Constitutional Gate) and understand which claims to file now vs. defer. Section 4 (Inter-process effectiveness) provides "Overall Effectiveness: HIGH" and "Recommendation: PROCEED to CARTOGRAPHER" (line 279). Actionable for go/no-go decision.
- **boundaries.md (8)**: Data ownership table (lines 143–155) shows which tier owns which artifacts. CARTOGRAPHER can read and know: spec.md is created by CARTOGRAPHER, read by GATEKEEPER and ARCHITECT, archived after run. Actionable. Gap: conflict resolution across tier boundaries not specified (if ARCHITECT reads spec and says "this requires a different tech stack," who resolves?).

**Fair (7)**: Mostly descriptive, some missing decision rules
- **novelty-catalogue.md (7)**: Lists 8 novelties with evidence and patent ranking. LEGAL can read and start patent filing. CARTOGRAPHER reading this would understand what mechanisms are implemented but not how to test them (no "success criteria" like unknowns.md provides). Gap: for each novelty, what would prove it's truly novel? Actionable for patent strategy, less so for technical validation.
- **inter-process-effectiveness.md (7)**: Identifies bottlenecks (5 listed, lines 126–147). COMMANDER reading this would understand SAGE amendment loop is a bottleneck and ORCHESTRATOR task dependency is a bottleneck. But no decision rule: "if amendment loop > N iterations, take action X." Gap: effectiveness claims (line 101: "~90% pass after 1–2 re-runs") are estimates not data; SAGE agent cannot use this to decide "is my gate working well?"
- **assumptions.md (7)**: 15 assumptions documented with validation methods. INVESTIGATOR reading this could execute A-005 experiment (endocrine efficacy) because method is documented (line 37: "Run 10 tasks, BANZAI with hormones vs baseline; measure ≥5% improvement on ≥2 metrics"). Actionable for research. Gap: assumes INVESTIGATOR will proactively run validation; no COMMANDER trigger documented ("when should this validation run?").

---

## Pass/Fail Thresholds

**Quality Gate**: Overall ≥ 7.0 to pass WHY1  
**Critical Threshold**: Overall < 6.0 blocks downstream (CARTOGRAPHER cannot proceed)

### Results

| Artifact | Overall | Threshold | Status |
|----------|---------|-----------|--------|
| glossary.md | 8.75 | ≥7.0 | **PASS** |
| mental-model.md | 8.0 | ≥7.0 | **PASS** |
| novelty-catalogue.md | 7.0 | ≥7.0 | **PASS** (marginal) |
| inter-process-effectiveness.md | 7.0 | ≥7.0 | **PASS** (marginal) |
| assumptions.md | 7.0 | ≥7.0 | **PASS** (marginal, Evidence=4 drags score) |
| boundaries.md | 7.25 | ≥7.0 | **PASS** |
| unknowns.md | 8.0 | ≥7.0 | **PASS** |
| synthesis-report.md | 7.75 | ≥7.0 | **PASS** |
| reasoning-journal.json | 7.5 | ≥7.0 | **PASS** |
| proof-status-table.md | 8.75 | ≥7.0 | **PASS** |

**Aggregate Score**: (8.75 + 8.0 + 7.0 + 7.0 + 7.0 + 7.25 + 8.0 + 7.75 + 7.5 + 8.75) / 10 = **76.0 / 10 = 7.6 / 10**

**Verdict**: All artifacts PASS individually (≥7.0). Aggregate PASSES (≥7.0).

---

## Dimension Summary

### Coverage: Average 8.3/10
- **Strengths**: Glossary, assumptions, unknowns, proof-status-table all comprehensive (8-9 range)
- **Weaknesses**: Inter-process-effectiveness (7) and boundaries (8) miss some details
- **Assessment**: Discovery covers all necessary ground. No major conceptual gaps.

### Consistency: Average 8.1/10
- **Strengths**: Glossary, proof-status-table, reasoning-journal highly consistent (8-9 range)
- **Weaknesses**: Novelty-catalogue (7) and inter-process-effectiveness (8) have labeling inconsistencies
- **Assessment**: Cross-artifact consistency good. Some internal ambiguities (overloaded terms, pass/fail language) but resolvable.

### Evidence: Average 6.6/10
- **Strengths**: Proof-status-table (8), glossary (8), synthesis-report (7) cite sources well
- **Weaknesses**: Assumptions (4), inter-process-effectiveness (5), boundaries (6) mostly estimate-based
- **Assessment**: Novelty claims well-evidenced (arxiv citations). Effectiveness claims largely unvalidated (estimates labeled as "(est.)"). This is the weakest dimension.

### Actionability: Average 7.7/10
- **Strengths**: Glossary, proof-status-table, unknowns all have clear next-step guidance (8-9 range)
- **Weaknesses**: Novelty-catalogue (7) and assumptions (7) less specific on validation triggers
- **Assessment**: Sufficient for CARTOGRAPHER and INVESTIGATOR to proceed. Some ambiguity on decision rules.

---

## Recommendations

### For CARTOGRAPHER (WHAT Phase)
- **Use**: glossary.md, mental-model.md, boundaries.md — these are comprehensive and well-structured
- **Be Cautious**: novelty-catalogue.md for understanding implemented mechanisms (mechanisms are real, but novelty claims are not validated)
- **Get Clarification**: assumptions.md on which assumptions block spec writing (none — all are design-level or post-implementation)

### For GATEKEEPER (ASSESS Phase)
- **Use**: unknowns.md to understand blocking factors (U-CA-004, U-008, U-003)
- **Use**: synthesis-report.md Section 4 (Inter-process Effectiveness) to understand quality gate effectiveness (HIGH overall despite unvalidated pass rates)
- **Be Aware**: Gate effectiveness claims (70%+ pass rate, 90% after amendments) are estimates, not measured

### For ARCHITECT (HOW Phase)
- **Use**: proof-status-table.md to understand which mechanisms are proven (NS-003 components: Grade A) vs gate-conditioned (CA overlays: all rows 6-10)
- **Be Aware**: Cannot design with Goal Stack, ACT-R Buffer, LIDA, GWT, Episodic Memory until U-CA-004 resolves
- **Use**: mental-model.md Section 4 (Critical Dependency Chains) to understand architecture constraints

### For INVESTIGATOR (Research)
- **Use**: unknowns.md to know exactly what experiments to run (U-001 through U-010, with success criteria)
- **Use**: assumptions.md Section "Validation method" to know how to validate each assumption
- **Priority**: U-005 (endocrine efficacy), A-004 (token cost), A-001 (Opus vs Sonnet), U-003 (SAGE validation)

---

## Evidence Grade Distribution

| Grade | Count | Artifacts |
|-------|-------|-----------|
| A+ (9) | 2 | glossary.md, proof-status-table.md |
| A (8-8.5) | 3 | mental-model.md, unknowns.md, synthesis-report.md |
| B+ (7-7.5) | 4 | boundaries.md, novelty-catalogue.md, inter-process-effectiveness.md, reasoning-journal.json |
| B (6-6.5) | 1 | assumptions.md (Evidence = 4, pulls overall to 7.0) |

---

## Issues Flagged for Rework

Per issues.md (WHY1 output):

| Issue | Artifact | Action | Before/After |
|-------|----------|--------|--------------|
| IS-001 (constitution.md missing) | novelty-catalogue.md, synthesis-report.md | Create artifact, re-validate NOVEL-006 | CRITICAL |
| IS-002 (A-001, A-004, A-005 unvalidated) | assumptions.md | Run experiments (U-005, cost measurement, Opus vs Sonnet) | HIGH |
| IS-003 (gate claims unproven) | inter-process-effectiveness.md, synthesis-report.md | Instrument runs; benchmark SAGE | HIGH |
| IS-005 (NOVEL-004, NOVEL-008 weak defensibility) | novelty-catalogue.md, synthesis-report.md | Defer patent filing until effectiveness proven | HIGH |
| IS-006 (42 agents not optimized) | assumptions.md, unknowns.md | Run ablation study; test alternate phase sequences | MEDIUM |

---

## Final Assessment

**Overall Quality Gate Score**: 7.6 / 10  
**Pass/Fail**: **PASS** (≥7.0 threshold met)  
**Recommendation**: Proceed to CARTOGRAPHER with noted caveats:
1. Address IS-001 (constitution.md) before running pre-dispatch governance tests
2. Address IS-004 (U-CA-004, NS-003 prototype) as blocking unknowns; cannot design with CA overlays yet
3. Address IS-002 and IS-003 before finalizing quality gate thresholds and model selections

**Readiness for Next Phase**: 6.5 / 10 (scores well on completeness, weak on validation; ready to proceed with cautions)

